Eliquis is owned by Bristol Myers Squibb.
Eliquis contains Apixaban.
Eliquis has a total of 2 drug patents out of which 0 drug patents have expired.
Eliquis was authorised for market use on 28 December, 2012.
Eliquis is available in tablet;oral dosage forms.
Eliquis can be used as prophylaxis of deep vein thrombosis and pulmonary embolism; reducing the risk of stroke and systemic embolism; treatment of pulmonary embolism (pe); reduce the risk of recurrent deep vein thrombosis (dvt); treatment of deep vein thrombosis (dvt); reduce the risk of recurrent pulmonary embolism; prophylaxis of deep vein thrombosis (dvt); reducing the risk of stroke; prophylaxis of pulmonary embolism.
The generics of Eliquis are possible to be released after 24 February, 2031.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6967208 | BRISTOL MYERS SQUIBB | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors |
Nov, 2026
(3 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9326945 | BRISTOL MYERS SQUIBB | Apixaban formulations |
Feb, 2031
(8 years from now) |
Drugs and Companies using APIXABAN ingredient
Market Authorisation Date: 28 December, 2012
Treatment: Prophylaxis of deep vein thrombosis and pulmonary embolism; Reducing the risk of stroke and systemic embolism; Treatment of pulmonary embolism (pe); Reduce the risk of recurrent deep vein thrombosis (dvt); Treatment of deep vein thrombosis (dvt); Reduce the risk of recurrent pulmonary embolism; Prophylaxis of deep vein thrombosis (dvt); Reducing the risk of stroke; Prophylaxis of pulmonary embolism
Dosage: TABLET;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic